FDA Approves AMBELVIST — Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals has secured FDA approval for AMBELVIST (gadoquatrone), an intravenous drug for obstructive jaundice slated for launch on June 12, 2026. This regulatory milestone positions the company to capitalize on a growing market for biliary treatments, potentially bolstering its portfolio during the late-stage development window.